Herriot Tabuteau, Axsome CEO (Photo by Owen Hoffmann/Patrick McMullan via Getty Images)
February 27, 2023 10:10 AM EST
R&D
FDA+

Ax­some says FDA wants more da­ta for Alzheimer’s ag­i­ta­tion la­bel ex­pan­sion, but read­out to come soon­er 

Kyle LaHucik

Biotech Correspondent

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

An­oth­er Bris­tol My­ers ex­ec goes to Aca­dia; David South­well takes CEO job at ARCH-backed can­cer biotech

As a chal­leng­ing first half nears a close, bio­phar­ma un­cer­tain­ty per­sists

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times